LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Lista de Ações・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Fechado

SetorSaúde

68.64 0.48

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

68.06

Máximo

69.53

Indicadores-chave
By Trading Economics
Rendimento	292M 150M
Vendas	-75M 377M
P/E Médio do Setor	24.112 50.102
EPS	1.221
Margem de lucro	39.832
Funcionários	423
EBITDA	-63M 218M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+17.8% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	501M 8.2B
Abertura anterior	68.16
Fecho anterior	68.64

Sentimento de Notícias

By Acuity

12%

88%

13 / 344 Ranking em Healthcare

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mai. de 2026, 16:52 UTC

Notícias Principais

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q Rev $1.76B >SQM

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q EPS $1.28 >SQM

26 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q EPS $11.61 >WEBC

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q Sales $179.6M >WEBC

26 de mai. de 2026, 21:48 UTC

Conversa de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 de mai. de 2026, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

26 de mai. de 2026, 20:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 de mai. de 2026, 19:17 UTC

Conversa de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 de mai. de 2026, 18:56 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 de mai. de 2026, 18:03 UTC

Conversa de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 de mai. de 2026, 17:42 UTC

Conversa de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 de mai. de 2026, 17:33 UTC

Conversa de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 de mai. de 2026, 17:21 UTC

Conversa de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 de mai. de 2026, 16:52 UTC

Conversa de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 de mai. de 2026, 16:43 UTC

Conversa de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 de mai. de 2026, 16:24 UTC

Conversa de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 de mai. de 2026, 16:21 UTC

Conversa de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 16:16 UTC

Conversa de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 de mai. de 2026, 16:01 UTC

Conversa de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 de mai. de 2026, 15:21 UTC

Conversa de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

17.8% parte superior

Previsão para 12 meses

Média 80.48 USD 17.8%

Máximo 96 USD

Mínimo 66.41 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

13 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.